ESC 365 - Rationale for and design of the SUBQ-HF clinical study.

HFA Premium Access

Rationale for and design of the SUBQ-HF clinical study.

Session: Furosemide 2.0: furosemide for subcutaneous administration: a novel tool in the management of the pre and post acute heart failure patient

Topic: Acute Heart Failure

Speaker: Professor G. Felker (Durham, US)

Sponsored by scPharmaceuticals

Event: HEART FAILURE 2016

Congress Presentation

Add to my library

About the speaker

Professor G Michael Felker

Duke University Medical Center, Durham (United States of America)

14 presentations

0 follower

3 more presentations in this session

Furosemide 2.0: a novel formulation of furosemide for subcutaneous administration.

Speaker: Professor B. Pitt (Ann Arbor, US)

Pharmacokinetics of furosemide following subcutaneous administration of a novel injectable formulation.

Speaker: Professor R. De Boer (Rotterdam, NL)

Initial clinical experience with subcutaneous furosemide in patients with fluid overload.

Speaker: Doctor S. Russell (Durham, US)

Access the full session

Furosemide 2.0: furosemide for subcutaneous administration: a novel tool in the management of the pre and post acute heart failure patient

Speakers: Professor G. Felker, Professor B. Pitt, Professor R. De Boer, Doctor S. Russell

About the event

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources